Adrian Hargrave, CEO of SEEEN, explains how the new funds will accelerate customer growth Watch the video here.

Less Ads, More Data, More Tools Register for FREE

UK launches trial combining different Covid vaccines

Thu, 04th Feb 2021 11:27

(Sharecast News) - The UK has launched the first trial in the world that explores mixing different Covid-19 vaccines for the first and second jab.
According to CNBC, the aim of the trial is to see if employing two dose vaccine regimes using different shots is as effective as using those from the same manufacturer, which would give vaccination programs more flexibility.

The trial is being led by the University of Oxford and run by the National Immunisation Schedule Evaluation Consortium.

"If we do show that these vaccines can be used interchangeably in the same schedule this will greatly increase the flexibility of vaccine delivery, and could provide clues as to how to increase the breadth of protection against new virus strains," Matthew Snape, chief investigator on the trial and associate professor in Paediatrics and Vaccinology at the University of Oxford said on Thursday.

Snape said the study was "tremendously exciting," before adding that "it will provide information vital to the rollout of vaccines in the UK and globally."

The trial, named "Covid-19 Heterologous Prime Boost study", will recruit over 800 volunteers aged 50 and above in England to evaluate the four different combinations of different vaccines.

There are concerns that mixing vaccines could make them less effective but Deputy Chief Medical Officer and Senior Responsible Officer for the study, Professor Jonathan Van-Tam, said that the research could even show that alternating vaccines could enhance the level of antibodies needed to fight the virus.

"It is also even possible that by combining vaccines, the immune response could be enhanced giving even higher antibody levels that last longer; unless this is evaluated in a clinical trial we just won't know. This study will give us greater insight into how we can use vaccines to stay on top of this nasty disease."

Related Shares

More News
Today 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Today 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals In...

3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the Europ...

3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommend...

2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worse...

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.